Santo Raffaele M.
- Country
- Italy
- Department
- Unit of Dermatology and Cosmetology
Research Overview
- Evaluation of Upadacitinib Efficacy, Safety, and Tolerability in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Therapy
- A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
Data & Insights
Has run more than one trial at 8 of 112 partner sites.
Specializations
Dermatological Research
The investigator specializes in studying non-segmental vitiligo, focusing on innovative therapeutic approaches for this autoimmune skin condition.
- Vitiligo Management
- Autoimmune Skin Disorders
- Systemic Therapy Development
Their research encompasses both adult and adolescent patient populations, investigating advanced treatment options for pigmentation disorders.
Therapeutic Innovation
The investigator's work centers on evaluating novel oral therapeutic solutions for dermatological conditions, with particular attention to treatment efficacy and patient safety.
- Oral Treatment Modalities
- Treatment Tolerability Assessment
- Clinical Safety Evaluation
Their research focuses on developing systematic approaches to treating chronic skin conditions requiring long-term management.
Clinical Expertise
The investigator demonstrates particular interest in systemic therapy applications for dermatological conditions, specifically targeting patients requiring comprehensive treatment approaches.
- Adolescent Dermatology
- Adult Dermatological Care
- Systematic Treatment Protocols
Their work encompasses comprehensive evaluation of adverse events and therapeutic effectiveness in dermatological interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.